Company intelligence
Belite Bio
Biotechnology Research
San Diego, US
51–200 employees
Founded 2018
2 public signals
About Belite Bio
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
Verified activity
Signals from Belite Bio
2 published signals
Legal & Regulatory
Belite Bio submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1, under the Sakigake Designation System.
Reported by Belite Bio
Presence & Recognition
Belite Bio announced participation in fireside chats at four investor conferences this September, including Wells Fargo 21st Annual Healthcare Conference, 2026 Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference.
Reported by Belite Bio